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cantly more likely than olanzapine-treated patients to ex-
perience multiple extrapyramidal symptoms. Olanzapine
patients were significantly more likely to experience
weight gain compared to risperidone and haloperidol pa-
tients. Regression models indicated that akathisia, hy-
pokinesia/akinesia, and the total number of extrapyrami-
dal symptoms were significantly associated with decreases
in the EQ-I and VAS scores from baseline to the 6-month
end-point. Weight gain and somnolence were not signifi-
cantly associated with EQ-I or VAS score changes from
baseline to the 6-month end-point. CONCLUSIONS:
The results demonstrated an inverse relationship between
adverse events and HRQoL in patients treated with an-
tipsychotics for schizophrenia. Akathisia, hypokinesia/
akinesia, and number of extrapyramidal symptoms had a
significant impact on HRQoL. The relationship between
weight gain or somnolence with HRQoL was not significant.
PMH7
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OBJECTIVE: To describe and compare treatment pat-
terns of patients with schizophrenia/schizo-affective dis-
order across 15 different countries. METHODS: Exami-
nation of baseline data from a prospective, multi-centre,
double blind, randomized comparison of quetiapine and
chlorpromazine. 381 patients were recruited from 12 Eu-
ropean countries plus Canada, Australia and South Af-
rica. An economic assessment (Client Services Receipt In-
ventory) included questions about health service use in
the 3 months prior to assessment and was adapted as far
as possible to obtain internationally comparable informa-
tion. Analyses are on country-level data, irrespective of
treatment group. RESULTS: Overall, 62% of patients
had a diagnosis of paranoid schizophrenia. Mean patient
age for each country ranged from 27 to 40 years and the
proportion of males ranged between 0–85%. There were
notable variations in service use. The proportion of pa-
tients in each country who reported using any health ser-
vices ranged between 69–100%. There was a large varia-
tion in the proportions using inpatient services (range
23–100%) and average length of stay (range 7–76 days).
Take-up of community-based services also differed across
countries: 0–75% seeing community psychiatric nurses,
0–46% seeing social workers and 0–75% seeing a gen-
eral practitioner. Graphical representation of treatment
patterns using starplots showed striking similarities be-
tween Australia and the UK; and Canada and Norway.
CONCLUSION: The pre-treatment baseline data are of
interest in their own right as they provide a unique op-
portunity to examine existing treatment patterns across a
large number of countries. Sources of treatment variation
across countries can be numerous and complex, depend-
ing on national, local and patient level factors. Such interna-
tional variations should lead us to question whether results
from a study conducted in one country can easily be used to
inform mental health purchasing decisions in another.
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OBJECTIVE: Pharmacoeconomic evaluation of selective
serotonin reuptake inhibitors (SSRIs) is becoming an im-
portant issue for regulatory and marketing purposes. At
the time of the launch of the drug, decision-tree models
(i.e. Markov and Monte-Carlo) provide the most realistic
projection data available. Designed to provide a large
range of information on outcome and cost, which are
based on various assumptions, the models enable deci-
sion-makers (physician, pharmacist, HMO, regulatory
etc.) to make informed, relative decisions. METHODS:
This poster illustrates five different model structures of
associated expenses that are incurred during the treat-
ment of Depression. The branches on these models be-
come progressively complex, and are based on the fol-
lowing five factors: (1) severity of the depression, (2) rate
of compliance, (3) success/failure rate, (4) patient drop-
out from the health care system (patient having no con-
tact with any medical institution or any medical doctor),
and (5) switch in case of failure or non tolerability. Costs
were taken from the literature using different sources.
RESULTS: SSRIs could be more or less cost-effective
than tricyclic antidepressants (TCAs) depending on whether
switch, compliance, success of treatment, dropout from
the health care system and disease have been taken into
consideration. Conversely, when the same information is
derived from different sources of the same country, the
cost-effectiveness ratio is significantly affected. More-
over, sensitivity analysis does not prevent such differ-
ences in outcome. CONCLUSIONS: Caution should be
used when reviewing such data as these results indicate
the tendency for gross discrepancy to exist between dif-
ferent methods of analysis. These results thus emphasize
the need for standardized pharmacoeconomic models.
The authors make arguments in support of this endeavor.
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OBJECTIVE: To compare subjective response and com-
pliance of olanzapine-treated patients and patients treated
with other antipsychotics in an observational prospective
study (EFESO). METHODS: Outpatients entered the
study when they received a new prescription of an antip-
sychotic drug. Patients treated with olanzapine (n 
2128), risperidone (n  417) and haloperidol (n  112)
were included in the analysis. Subjective response was
measured using the 10-item version of the Drug Attitude
Inventory (DAI-10). Treatment compliance was mea-
sured using a physician-rated 4 point categorical scale.
Subjective response and compliance were compared be-
tween the treatment groups. Data were collected at base-
line and after 3 and 6 months. RESULTS: Overall mean
doses were respectively 13 mg, 5.4 mg and 13.6 mg for
olanzapine, risperidone and haloperidol treated patients.
All three groups had a positive subjective response to
treatment. Olanzapine treated patients had significantly
higher DAI-10 score compared to both risperidone and
haloperidol treated patients at 3 months (P  0.003 and
P  0.001 respectively) and at 6 months (P  0.001 vs
risperidone and haloperidol). Risperidone-treated patients
had a higher DAI-10 score compared to haloperidol-
treated patients at both 3 months and 6 months (P  0.003).
Olanzapine-treated patients had significantly better treat-
ment compliance compared to both risperidone and halo-
peridol treated patients at 6 months (P  0.001 and P 
0.022 respectively). CONCLUSION: Despite the limita-
tions of an observational study, these results suggest that
in routine clinical practice, olanzapine-treated patients
exhibit a superior subjective response and compliance
compared to risperidone and haloperidol treated patients.
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OBJECTIVE: A model was developed to assess the clinical
outcome and costs of an intensive deinstitutionalization
strategy called Intensive Case Management (ICM) in com-
parison to Standard Case Management (SCM) for persons
suffering of chronic schizophrenia and long term hospital-
ized (1 year). METHODS: A Markov Model was con-
structed to describe the different possibilities of case man-
agement of long term hospitalized schizophrenic patients.
The Markov states were classified to one of five categories
hospital, institution, outpatient, dropout, and death, fol-
lowed by either success or failure of the adopted case man-
agement. Clinical, functioning improvement, and patient
discharge from acute care unit define success here. The
Markov process iterates in 1-year cycles until the 5-year.
Model probabilities are gathered from an ongoing ambi-
spective cohort of patients assigned to ICM or SCM in the
catchment area of Clermont-Ferrand. Control patients
(SCM) were/are retrospectively chosen on the premise that
they could have been selected for ICM group. Service utili-
zation data are obtained from patient medical and adminis-
trative record while direct costs are obtained from the ana-
lytical accounting system of the catchment area. RESULTS:
Based on the primary data collected (ICM: n  42, SCM:
n  28), the outcomes of the two types of care showed,
that the ICM was more effective in terms of success over
the first one-year period 59% of the patients experienced a
success as opposed to 25% in SCM. It was also shown that
readmission to hospital was more likely in the SCM (67%
as opposed to 22% in ICM). A threshold analysis will be
performed in order to evaluate at which point ICM will
be too costly for the hospital budget. CONCLUSIONS:
With these outcome results, ICM is shown to be more ef-
fective than SCM. The model will be used to generate cost-
effectiveness ratios, budgetary previsions for large-scale im-
plementation of ICM, in order to help decision-makers in
policy-making for mental health care organizations.
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OBJECTIVE: To assess the concordance of self reports,
parental reports and urine drug bioassays as measures of
drug use in adolescents treated for chemical dependency.
Questions addressed are, (1) what is the concordance be-
tween self reports, parental reports and bioassays? (2)
does the concordance vary over time? METHODS: Anal-
yses are based on panel study data from 119 adolescents
and their parents. Each adolescent completed drug treat-
ment at the same facility in the same time period. To as-
sess treatment effectiveness adolescents and their parents
were followed prospectively and interviewed separately
with a standardized questionnaire at 3, 6, 9 and 12 months
post treatment. Random urine bioassays via enzyme im-
munoassay were administered during the study. Each ad-
olescent was drug tested a minimum of 9 times. RESULTS:
Eighty-one percent of the adolescents self-reported sub-
stance use during the study period and 31% had a posi-
tive urine bioassays (Cohen’s Kappa 	  .077, P  .388).
Sixty-five percent reported using alcohol while there were
no bioassays positive for alcohol. The concordance be-
tween reported marijuana use and positive urine bioas-
says showed that 48% reported using marijuana while
29% had a positive marijuana bioassay (	  .40, P 
.006). Fifty-two percent reported using several different
substances but had as many as ten negative drug screens.
Sixty four percent of the parents of the adolescents who
reported use confirmed that their child used in the first
